Covid-19 roundup: UK and CureVac join forces to fight emerging variants; Sanofi and GlaxoSmithKline post snapshot of PhI/II vaccine data
The UK’s Vaccines Taskforce will work with CureVac to track new variants and generate vaccine candidates against them, according to a statement. As part of the deal, the UK will get an initial supply of 50 million doses of the variant vaccines. And CureVac will have manufacturing strategies in place to ramp up production for the UK “if and when needed” over the next three years.
“At CureVac, we believe we have the ability to quickly adapt our mRNA technology to address current variants and prepare for the emergence of new strains,” CureVac’s chief business and commercial officer Antony Blanc said in a statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
